An Alzheimer’s vaccine developed by Australian scientists has been tested in animals and is expected to be tested in humans within two years, with success expected to be available within a decade,media reported. Nikolai Petrovsky, a professor at Flinders University, said the team had successfully completed animal trials and hoped to start human trials within the next 18 to 24 months.
He is optimistic that the vaccine will be available in the next five to 10 years.
The vaccine was reportedly developed by Professor Petrovsky and others, and the Institute of Molecular Medicine and the University of California are leading and funding the study, which has been under way for 20 years.
Professor Petrovsky said the vaccine was designed as both a preventive measure and a treatment.
The vaccine was designed to allow antibodies to detect and digest these lumps in the brain, reversing or preventing the effects of the disease, the Daily Mail of London reported. This dual vaccine is unlike any current treatment because some drugs can help alleviate symptoms, but none of them are targeted at the brain.
The mice in the experiment had earlier been genetically programmed to develop Alzheimer’s disease. When the researchers vaccinated the mice, they found that Alzheimer’s disease in mice was effectively alleviated. “We were able to prevent memory loss in mice, and the next step in the study was to apply it to human clinical trials. “
“It’s exciting to be on another decade. If we can make the Alzheimer’s vaccine work in human trials, it will undoubtedly be a breakthrough in the next 10 years! He also said the vaccine could be available as soon as five years, not more than 10 years at most.
“The advent of this vaccine is revolutionary, and while it won’t be tomorrow, it shows that human medicine is an exciting step in the right direction. “
Alzheimer’s disease, also known as Alzheimer’s disease, has symptoms including memory impairment, aphasia, and behavioural changes. Past studies have suggested that a major cause of the disease is the accumulation of abnormally formed proteins in the brain that interfere with cell-to-cell communication.
Professor Petrovsky says Alzheimer’s is one of the biggest medical problems and will only worsen as the population ages.
However, while the outlook is very promising, the attitude of the relevant institutions towards the application of this innovative technology remains cautious. They say more clinical trials are needed to improve.